Anticancer Drug Specificity

These features can distinguish malignant cells from healthy tissues and provide molecular points for therapeutic recognition. A drug may be selected to exploit abnormal signaling or a tumor’s impaired ability to repair DNA, increasing the likelihood that cancer cells experience a stronger treatment effect. Their presence can therefore guide targeted treatment selection rather than relying only on tumor location.

Targeted therapies act through recognition of cancer-associated molecular features, whereas antibody-drug conjugates use an antibody-linked design to direct a drug toward an enriched tumor antigen. Tumor-selective prodrugs add another layer by concentrating or activating treatment within the tumor. These approaches pursue the same therapeutic goal through different combinations of recognition, delivery, and activation.

Tumors may differ in their signaling proteins, DNA-repair defects, or levels of cancer-associated antigens, so a feature that supports treatment in one tumor may be less prominent in another. Treatment can also select for resistant cancer cells. Consequently, initial specificity does not guarantee a lasting response, making predictive biomarkers and continued evaluation important.

Predictive biomarkers help indicate whether a tumor contains a molecular feature that a therapy is designed to recognize or exploit. Clinicians can use this information to match treatment more closely to the tumor’s biology, rather than assuming that all cancers of the same general type will respond alike. Biomarker-guided selection supports more precise treatment planning.

Treatment evaluation should consider both the intended cancer response and the effects on healthy tissues. Specificity aims to improve benefit while limiting toxicity, but tumor differences and resistance can alter that balance over time. Ongoing assessment helps determine whether the selected therapy remains appropriate and whether treatment strategies, including combinations, should be reconsidered.

Specificity provides a basis for combining therapies that address complementary tumor features or treatment vulnerabilities. A targeted approach may be considered alongside another strategy when a single molecular dependence is insufficient or resistance emerges. The rationale is not simply to add drugs, but to use tumor biology and ongoing evaluation to improve treatment selection while remaining attentive to toxicity.